BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 1909607)

  • 1. Effect of ritanserin, specific 5HT-2 antagonist, on PRL secretion in normal subjects and in different hyperprolactinaemic conditions.
    Falaschi P; Rosa M; Rocco A; D'Urso R; Proietti A; Melis GB
    Clin Endocrinol (Oxf); 1991 Jun; 34(6):449-53. PubMed ID: 1909607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prolactin-secreting pituitary adenomas: prolactin dynamics before and after transsphenoidal surgery.
    Barbarino A; de Marinis L; Menini E; Anile C; Maira G
    Acta Endocrinol (Copenh); 1979 Jul; 91(3):397-409. PubMed ID: 112818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reciprocal pattern of the TSH and PRL responses to dopamine receptor blockade in women with physiological or pathological hyperprolactinaemia.
    Massara F; Camanni F; Martra M; Dolfin GC; Müller EE; Molinatti GM
    Clin Endocrinol (Oxf); 1983 Feb; 18(2):103-10. PubMed ID: 6851194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benserazide and nomifensine in the diagnosis of prolactin-secreting pituitary adenomas.
    Pontiroli AE; Loda G; Roggia A; Scagliola P; Falsetti L
    Acta Endocrinol (Copenh); 1982 Oct; 101(2):171-9. PubMed ID: 7136447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distinctive features of prolactin secretion in acromegalic patients with hyperprolactinaemia.
    Serri O; Robert F; Comtois R; Jilwan N; Beauregard H; Hardy J; Somma M
    Clin Endocrinol (Oxf); 1987 Oct; 27(4):429-36. PubMed ID: 3124991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lack of plasma prolactin response to intravenously injected vasoactive intestinal polypeptide in patients with prolactin-secreting adenoma.
    Kaji H; Chihara K; Kita T; Kashio Y; Okimura Y; Fujita T
    Acta Endocrinol (Copenh); 1985 Dec; 110(4):445-50. PubMed ID: 4090907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The diagnostic value of pharmacodynamic tests in the hyperprolactinaemic syndrome.
    Ayalon D; Persitz E; Ravid R; Jedwab G; Avidan S; Cordova T; Harell A
    Clin Endocrinol (Oxf); 1979; 11(2):201-15. PubMed ID: 114343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of dopaminergic tone in hyperprolactinemia. III. Thyroid-stimulating hormone response to metoclopramide in differential diagnosis and postoperative follow-up of prolactinoma patients.
    De Marinis L; Mancini A; Minnielli S; Masala R; Anile C; Maira G; Barbarino A
    Metabolism; 1985 Oct; 34(10):917-22. PubMed ID: 4046835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interaction of dopaminergic and antiserotoninergic drugs in the control of prolactin and LH release in normal women.
    Pontiroli AE; Alberetto M; Pellicciotta G; De Castro e Silva E; De Pasqua A; Girardi AM; Pozza G
    Acta Endocrinol (Copenh); 1980 Mar; 93(3):271-6. PubMed ID: 7376792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of sulpiride on plasma prolactin levels in women with puerperal or pathological hyperprolactinaemia.
    Massara F; Camanni F; Belforte L; Campagnoli C; Novi RF; Molinatti GM
    Acta Endocrinol (Copenh); 1980 Oct; 95(2):145-50. PubMed ID: 7435113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Twenty-four hour secretory pattern of prolactin in hyperprolactinaemic patients with pituitary micro- and macroadenomas.
    Seki K; Uesato T; Kato K; Shima K
    Acta Endocrinol (Copenh); 1984 Aug; 106(4):433-6. PubMed ID: 6475455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of two inhibitory tests (nomifensine and L-dopa + carbidopa) for the diagnosis of hyperprolactinaemic states.
    Moriondo P; Travaglini P; Nissim M; Faglia G
    Clin Endocrinol (Oxf); 1980 Dec; 13(6):525-33. PubMed ID: 7226570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The preoperative and postoperative investigation of TSH and prolactin release in the management of patients with hyperprolactinaemia due to prolactinomas and nonfunctional pituitary tumours: relationship to adenoma size at surgery.
    Scanlon MF; Peters JR; Salvador J; Richards SH; John R; Howell S; Williams ED; Thomas JP; Hall R
    Clin Endocrinol (Oxf); 1986 Apr; 24(4):435-46. PubMed ID: 3091297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolactin-releasing effect of domperidone in normoprolactinemic and hyperprolactinemic subjects.
    Camanni F; Genazzani AR; Massara F; La Rosa R; Cocchi D; Müller EE
    Neuroendocrinology; 1980; 30(1):2-6. PubMed ID: 7354887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dopaminergic mechanisms regulating prolactin secretion in patients with prolactin-secreting pituitary adenoma. Long-term studies after selective transsphenoidal surgery.
    Barbarino A; De Marinis L; Anile C; Menini E; Merlini G; Maira G
    Metabolism; 1982 Nov; 31(11):1100-4. PubMed ID: 6813636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Altered dopaminergic regulation of thyrotrophin release in patients with prolactinomas: comparison with other tests of hypothalamic-pituitary function.
    Scanlon MF; Rodriguez-Arnao MD; McGregor AM; Weightman D; Lewis M; Cook DB; Gomez-Pan A; Hall R
    Clin Endocrinol (Oxf); 1981 Feb; 14(2):133-43. PubMed ID: 6790201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ritanserin, a 5-HT2 receptor antagonist, does not modify ECT-induced prolactin release.
    Papakostas Y; Markianos M; Papadimitriou G; Stefanis C
    Psychopharmacology (Berl); 1990; 100(2):206-8. PubMed ID: 2106150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prolactin secretion from human prolactinomas perifused in vitro: effect of TRH, prostaglandin E1, theophylline, dopamine and dopamine receptor blockers.
    Chihara K; Iwasaki J; Minamitani N; Kaji H; Kodama H; Fujita T; Shirataki K; Tamaki N; Matsumoto S
    Acta Endocrinol (Copenh); 1984 Jan; 105(1):6-13. PubMed ID: 6421041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prolactin and growth hormone responses to dermorphin in patients with prolactin-secreting pituitary adenoma.
    degli Uberti EC; Trasforini G; Salvadori S; Margutti A; Rotola C; Bianconi M; Teodori V; Tomatis R; Pansini R
    Metabolism; 1985 Sep; 34(9):874-9. PubMed ID: 4033428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dysfunction of dopaminergic regulation of prolactin in patients with functioning and nonfunctioning pituitary adenomas and craniopharyngiomas.
    Martinez-Campos A; Cornejo J; Garza-Flores J; Velasco F
    Fertil Steril; 1985 Oct; 44(4):471-7. PubMed ID: 4054318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.